Dal gene study
Webdal-gene Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population with a Recent ACS This study is in follow-up. Primary Objective: A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. WebJun 8, 2024 · DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary …
Dal gene study
Did you know?
WebThe trial aims to reduce major adverse cardiovascular events (MACE). The dal-GenE trial is fully recruited, passed a futility analysis in January 2024, and trial completion is expected … WebJan 17, 2024 · Dal-GenE was a double-blind, parallel-group, placebo-controlled, randomized trial comparing orally administered dalcetrapib 600 mg once daily with placebo in a 1:1 ratio. 12 The randomization was...
WebThe original dal-OUTCOMES study was designed to maximize the anti- atherosclerotic effects that appear to be more readily modifiable during the early post-ACS phase of the … WebApr 5, 2024 · As a result, the sample size of the dal-GenE study will be increased to 6000 patients while maintaining the originally projected recruitment timelines of year-end 2024," commented Dr. Jean-Claude ...
WebDalCor is set to increase enrolment in its ongoing dal-GenE trial, a Phase III clinical study of dalcetrapib, from 5000 to 6000 patients. The development is based on better than expected enrolment results witnessed by dal-GenE, which has so far randomised a total of 4300 patients around five months ahead of enrolment projections. WebApr 26, 2016 · DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib …
WebJul 20, 2024 · Methods and results dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1–3 months and the AA genotype at variant rs1967309 in the ADCY9 gene.
WebAug 23, 2016 · The dal-GenE study will enroll a total of 5000 patients across 1000 centers in 33 countries including the U.S., Canada, New Zealand, the United Kingdom, France, Spain, Sweden, Finland, Belgium,... hbot corexyWebJul 27, 2024 · It is currently being evaluated in the dal-GenE Phase 3 cardiovascular clinical outcomes trial aiming to deliver a relative risk reduction of 15% or greater for major … hbot complicationsWebStudy design dal-GenE is a double-blind, parallel group, placebo-controlled randomized trial in patients recently hospital-ized for ACS and confirmed to have the AA genotype at hbot crohn\u0027s diseaseWebApr 1, 2024 · Study design dal-GenE is a double-blind, parallel group, placebo-controlled randomized trial in patients recently hospitalized for ACS and confirmed to have the AA genotype at variant rs1967309 in the ADCY9 gene. goldblum and pollinsWebApr 4, 2024 · In this study, we evaluated the gene expression of the pulmonary SP (SP-A1, SP-A2, SP-B, SP-C and SP-D) in human NCI-H441 cells following an A. fumigatus infection. We tested the effect of DAL, DHN-melanin-deficient, GAG-deficient and GM-deficient mutant A. fumigatus strains as well as culture filtrates incubated with cells for 4 and 8 h. hbot credentialWebJul 27, 2024 · DalCor would like to thank all the patients, investigators, and study sites for their continued participation in the dal-GenE study. About DalCor DalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision … goldblum and hessWebApr 26, 2016 · LONDON and MONTREAL, April 26, 2016 – DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. gold bluffs beach permit